Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis.
BACKGROUND
Although the DNA of parvovirus B19 (B19V) is frequently detected in patients with dilated cardiomyopathy or myocarditis, whether the parvovirus causes disease is questionable, since even in healthy individuals the virus persists in various tissues. The same question applies to human bocavirus (HBoV). We have determined the prevalence and quantity of B19V and HBoV DNA in heart tissue of patients who were not experiencing virus-related heart diseases and analyzed whether the seroprevalence corresponded to DNA prevalence in the heart.


METHODS
Samples of left-atrium heart tissue and serum were obtained from 100 patients who underwent open-heart surgery. Serum immunoglobulin (Ig) G and IgM against proteins encoded by B19V and HBoV were detected by enzyme-linked immunoabsorption assay and immunoblotting. B19V and HBoV DNA concentrations were determined by quantitative real-time polymerase chain reaction (PCR) in heart tissue and serum samples. Nested PCRs for VP1, K71, and GT3 identified the B19V genotypes.


RESULTS
The prevalences of serum IgG specific for B19V and HBoV were 85% and 96%, respectively. Of all the patients, 85% had B19V DNA detected in heart tissues, and 4% displayed low-level B19V viremia, whereas only 5% of heart tissue samples and none of the serum samples demonstrated HBoV DNA. The sensitivity of B19V serological testing for B19V DNA in heart samples was 0.96 (95% confidence interval, 0.92-1.0). Specificity was 0.8 (95% confidence interval, 0.6-1.0), and the positive predictive value was 0.96 (95% confidence interval, 0.92-1.0). B19V genotypes 1 and 2 were present in 11% and 89% of heart tissues samples, respectively. B19V genotype 3 was not detected in any of the samples.


CONCLUSIONS
Our data suggest that B19V but not HBoV demonstrates a lifelong persistence in the heart. The detection of B19V DNA in heart tissue showed no correlation with clinical symptoms. We strongly recommend that serological testing become a standardized procedure for future studies, to obtain representative data concerning the prevalence of B19V in the heart.
Kuethe
Friedhelm
F
Department of Medicine, University of Dresden, Dresden, Germany. Friedhelm.Kuethe@uniklinikum-dresden.de
Lindner
Juha
J
Matschke
Klaus
K
Wenzel
Juergen J
JJ
Norja
Päivi
P
Ploetze
Katrin
K
Schaal
Sarah
S
Kamvissi
Virginia
V
Bornstein
Stefan R
SR
Schwanebeck
Uta
U
Modrow
Susanne
S
D000368:Aged; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D036022:Capsid Proteins / Q000276:immunology; D002311:Cardiomyopathy, Dilated; D004279:DNA, Viral / Q000235:genetics*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005838:Genotype; D006321:Heart / Q000821:virology*; D056661:Human bocavirus / Q000235:genetics* / Q000276:immunology; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D009205:Myocarditis; D010322:Parvoviridae Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000821:virology; D016732:Parvovirus B19, Human / Q000235:genetics* / Q000276:immunology; D016133:Polymerase Chain Reaction; D015995:Prevalence
D000914:Antibodies, Viral; D036022:Capsid Proteins; D004279:DNA, Viral